Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 215.6 SEK 3.65%
Market Cap: 29.2B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Other Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Other Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Assets CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Other Assets
kr9.9B
CAGR 3-Years
188%
CAGR 5-Years
87%
CAGR 10-Years
49%
Biogaia AB
STO:BIOG B
Other Assets
kr165.2m
CAGR 3-Years
215%
CAGR 5-Years
99%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Probi AB
STO:PROB
Other Assets
kr359.8m
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
63%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Assets
kr9.7B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
20%
BioArctic AB
STO:BIOA B
Other Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
29.2B SEK
Industry
Biotechnology

Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.

VITR Intrinsic Value
136.75 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Other Assets?
Other Assets
9.9B SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Other Assets amounts to 9.9B SEK.

What is Vitrolife AB's Other Assets growth rate?
Other Assets CAGR 10Y
49%

Over the last year, the Other Assets growth was -31%. The average annual Other Assets growth rates for Vitrolife AB have been 188% over the past three years , 87% over the past five years , and 49% over the past ten years .

Back to Top